The 3 best performing ASX shares of the week of 5 December 2022

Marc Kennis Marc Kennis, December 12, 2022

The 3 best performing ASX shares in the week of 5 December 2022

 

The 3 best performing ASX shares of the week starting 5 December 2022 were Tombador Iron (ASX:TI1), up 38.1%, Macarthur Minerals (ASX:MIO), up 25%, and Cardiex (ASX:CDX), up 22.2%.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

1. Tombador Iron (ASX:TI1)

Industry: Resources

Our top 3 best performing ASX shares kicks off with Tombador Iron (ASX:TI1), which owns 100% of the fully permitted Tombador Iron Ore mine located in Bahia State Brazil. Tombador commenced production of premium-grade lump and fines hematite iron ore in May 2021 from a low-capex open-pit mining operation.

Market Cap: $62m

12 month high / low: $0.019 – $0.055

 

Tombador Iron

 

 

2. Macarthur Minerals (ASX:MIO)

Industry: Resources

Macarthur Minerals (ASX:MIO) is an iron ore development, gold and lithium exploration company that is focused on bringing to production its 100% owned Western Australia iron ore projects.

Market Cap: $33m

12 month high / low: $0.125 – $0.64

 

Macarthur Minerals

 

 

3. Cardiex (ASX:CDX)

Industry: Healthcare

Cardiex Limited (ASX:CDX) rounds out our top 3 best performing ASX shares this week. CDX is an ASX listed public company with operations in medical technology, wearable devices and telehealth, providing digital and device-based solutions for large-scale population health disorders with significant market scale. Its current focus is cardiovascular disease (CVD) and heart health.

Market Cap: $49m

12 month high / low: $0.25 – $0.72

 

Cardiex

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

 

Blog Categories

Get the Latest Insider Trades on ASX!

Recent Posts

AMA Group (ASX:AMA) recovery is now being tested by whether cash flow can sustain the turnaround

AMA Group (ASX: AMA)’s recovery story is now being tested by whether improving earnings can translate into durable cash flow…

Radiopharm Theranostics (ASX: RAD) is increasingly defined by whether RAD101 can justify a registrational pathway

Radiopharm Theranostics (ASX:RAD) is increasingly defined by whether its lead imaging asset RAD101 can convert encouraging mid-stage data into a…

3P Learning (ASX:3PL) must arrest school churn to protect its valuation

3P Learning (ASX: 3PL)’s valuation now hinges on whether the business review can arrest B2B school churn and declining revenue…